Sector Atlas · Updated June 30, 2026

The Healthcare & MedTech Stock Atlas

Every major publicly traded U.S. healthcare specialty, mapped with live analyst sentiment, direct company links, sample portfolios from aggressive to conservative, and the emerging names with the most exponential upside.

❤️ Cardiology & Cardiovascular Surgery 🦴 Orthopedics 🔬 Diagnostics & Imaging 🤖 Surgical Robotics 💊 Large-Cap Pharma 🧬 Biotech 🛡️ Managed Care 🏥 Hospitals 💻 Healthcare IT 🩸 Diabetes Care 🦷 Dental & Vision 📊 Sample Portfolios 🚀 Emerging Growth

Before you read on: this page is for general informational and educational purposes only. It is not investment advice, and the author is not a financial advisor. Analyst consensus ratings and price targets are time-sensitive snapshots, sourced from stockanalysis.com, TipRanks, MarketBeat, Public.com, and Simply Wall St as of June 29–30, 2026, and can shift within days around earnings or FDA news. On the new "Price" column: bolded values are recent reference prices captured during research; every other ticker links straight to a live quote instead of showing a number that could already be stale. Always verify current data before acting, and speak with a licensed advisor about your own situation.

1

Cardiology & Cardiovascular Devices

Pacemakers, stents, structural heart valves, and the surgical robots edging into the cath lab.

Ticker	Company	Cap	Rating	Price	Target	What they do
MDT	Medtronic	Large	Buy	$81	~$98–$108	Pacemakers, defibrillators, cardiac ablation tech
ABT	Abbott Laboratories	Large	Buy	$92.71	~$128	Cardiovascular, diabetes & diagnostics conglomerate
BSX	Boston Scientific	Large	Hold	$42.47	~$115–$130	Electrophysiology (FARAPULSE), structural heart (WATCHMAN)
EW	Edwards Lifesciences	Large	Mixed	$90.71	—	Structural heart valves (TAVR), critical care monitoring
ATRC	AtriCure	Small	Mixed	Check live price	—	Atrial fibrillation surgical ablation devices
CRDL	Cardiol Therapeutics	Small	Strong Buy	$0.99	~$8	Clinical-stage CBD-based anti-inflammatory heart drugs
OBIO	Orchestra BioMed	Small	Speculative	Check live price	—	Bioelectronic hypertension therapy (AVIM), partnered with Medtronic
JNJ	Johnson & Johnson (Abiomed & Shockwave)	Large	Buy	$254	~$257	Owns Impella heart pumps (Abiomed) and intravascular lithotripsy (Shockwave) for calcified artery treatment
PEN	Penumbra	Mid	Buy-leaning	$317.63	—	Thrombectomy systems for vascular and neurovascular clot removal
NARI	Inari Medical	Mid	Buy-leaning	Check live price	—	Catheter-based devices to remove blood clots in venous thromboembolism (DVT/PE)
SILK	Silk Road Medical	Small	Mixed	Check live price	—	TransCarotid Artery Revascularization (TCAR) system for stroke prevention
AORT	Artivion (formerly CryoLife)	Small/Mid	Buy-leaning	Check live price	—	Aortic disease devices, cardiac surgery grafts, and tissue products
LIVN	LivaNova	Mid	Mixed	Check live price	—	Cardiopulmonary bypass/perfusion systems used in open-heart surgery
HAE	Haemonetics	Mid	Buy-leaning	Check live price	—	Blood management and autotransfusion systems used during cardiac surgery
MMSI	Merit Medical Systems	Small/Mid	Buy-leaning	Check live price	—	Cardiovascular catheters, guidewires, and embolization devices
ANGO	AngioDynamics	Small	Mixed	Check live price	—	Vascular access devices, peripheral vascular and venous disease treatment
SRDX	Surmodics	Small	Mixed	Check live price	—	Drug-coated balloon technology and coatings licensed to cardiovascular device makers
ITGR	Integer Holdings	Mid	Buy-leaning	Check live price	—	Manufactures components (batteries, leads) used inside pacemakers and defibrillators
IRTC	iRhythm Technologies	Small/Mid	Buy-leaning	Check live price	—	Zio wearable patch for ambulatory cardiac arrhythmia monitoring
CNMD	CONMED	Small/Mid	Mixed	Check live price	—	Surgical devices used across cardiac and general surgery procedures
INSP	Inspire Medical Systems	Mid	Buy-leaning	$41.75	—	Implantable neurostimulation for sleep apnea, a major cardiovascular risk factor
GETI-B.ST	Getinge (Stockholm-listed)	Mid/Large	Mixed	Check live price	—	Cardiopulmonary support, intra-aortic balloon pumps, surgical workflow equipment

2

Orthopedics

Joint replacements, spine hardware, and the robotic navigation systems reshaping the OR.

Ticker	Company	Cap	Rating	Price	Target	What they do
SYK	Stryker	Large	Buy	$304.69	—	Orthopedic implants, Mako robotics, MedSurg
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	Knee/hip implants, ROSA robotics, spine, dental
JNJ	J&J DePuy Synthes	Large	Buy	$254	~$257	Orthopedic reconstruction & trauma
GMED	Globus Medical	Mid	Buy-leaning	Check live price	—	Spine implants, ExcelsiusGPS robotic spine surgery
SNN	Smith+Nephew	Mid	Hold	Check live price	—	Orthopedics, sports medicine, wound care
AXGN	Axogen	Small	Buy-leaning	Check live price	—	Peripheral nerve repair
ATEC	Alphatec Holdings	Small	Buy-leaning	Check live price	—	Spine surgery technology
ENOV	Enovis	Mid	Mixed	Check live price	—	Reconstructive & prevention/recovery orthopedics

3

Diagnostics & Imaging

Lab testing networks, imaging centers, and the liquid-biopsy upstarts chasing earlier cancer detection.

Ticker	Company	Cap	Rating	Price	Target	What they do
DGX	Quest Diagnostics	Large	Mixed (Hold-leaning)	$195	~$190–$220	Nationwide clinical lab testing
LH	Labcorp	Large	Buy-leaning	Check live price	—	Lab testing & drug development services
GEHC	GE HealthCare	Large	Buy-leaning	$63.72	—	MRI, CT, ultrasound imaging equipment
TMO	Thermo Fisher Scientific	Large	Buy	Check live price	—	Life sciences tools, diagnostics, lab equipment
DHR	Danaher	Large	Buy-leaning	Check live price	—	Diagnostics, life sciences, biotech tools
RDNT	RadNet	Small/Mid	Buy-leaning	$58	—	Outpatient imaging + AI imaging division
GH	Guardant Health	Mid	Buy	$140	—	Liquid biopsy cancer genomic testing
EXAS	Exact Sciences	Mid	Buy-leaning	Check live price	—	Cancer screening (Cologuard)
NTRA	Natera	Mid	Buy	Check live price	—	Genetic testing, prenatal & oncology
TXG	10x Genomics	Small	Mixed	Check live price	—	Single-cell and spatial genomics tools

4

Surgical Robotics & Broad MedTech

The da Vinci-class platforms hospitals are betting their capital budgets on.

Ticker	Company	Cap	Rating	Price	Target	What they do
ISRG	Intuitive Surgical	Large	Strong Buy	$412	~$580–$615	da Vinci & Ion robotic surgical platforms
MDT	Medtronic	Large	Buy	$81	~$98–$108	Hugo robotic-assisted surgery system
SYK	Stryker	Large	Buy-leaning	$304.69	—	Mako robotic orthopedic surgery
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	ROSA robotic knee/hip navigation
ASXC	Asensus Surgical	Small	Speculative	Check live price	—	Digital laparoscopic surgical robotics
TMDX	TransMedics	Mid	Buy-leaning	Check live price	—	Organ transplant preservation/logistics tech
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL) for vision

5

Pharmaceuticals (Large-Cap)

GLP-1s, oncology blockbusters, and the patent-cliff dramas driving 2026 sentiment.

Ticker	Company	Cap	Rating	Price	Target	What they do
LLY	Eli Lilly	Large (~$700B+)	Strong Buy	$1,117	~$1,220–$1,250	GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound)
JNJ	Johnson & Johnson	Large (~$565B)	Buy	$254	~$257	Diversified pharma, immunology, oncology, MedTech
ABBV	AbbVie	Large (~$383B)	Buy/Hold	Check live price	—	Immunology post-Humira (Skyrizi, Rinvoq)
MRK	Merck & Co.	Large (~$302B)	Hold	Check live price	—	Keytruda oncology franchise, facing patent cliff
AZN	AstraZeneca	Large (~$291B)	Buy-leaning	Check live price	—	Oncology, cardiovascular/metabolic, biologics
PFE	Pfizer	Large	Hold	$24.29	—	Diversified pharma, post-COVID turnaround
BMY	Bristol Myers Squibb	Large	Hold-leaning	Check live price	—	Oncology, immunology
NVO	Novo Nordisk	Large	Mixed	Check live price	—	GLP-1 drugs (Ozempic/Wegovy)
GILD	Gilead Sciences	Large	Buy-leaning	Check live price	—	HIV franchise, growing oncology (Trodelvy)
AMGN	Amgen	Large	Buy-leaning	Check live price	—	Immunology, oncology, obesity pipeline (MariTide)

6

Biotech (Mid/Small-Cap)

Gene therapy, gene editing, and the autoimmune/rare-disease names with binary catalysts ahead.

Ticker	Company	Cap	Rating	Price	Target	What they do
VRTX	Vertex Pharmaceuticals	Large	Buy	Check live price	—	Cystic fibrosis monopoly, Casgevy gene therapy
REGN	Regeneron Pharmaceuticals	Large	Buy-leaning	Check live price	—	Eylea eye drug, Dupixent (with Sanofi)
ARGX	argenx	Mid/Large	Buy	Check live price	—	FcRn blocker Vyvgart across autoimmune indications
SRPT	Sarepta Therapeutics	Mid	Hold	$18	~$19	Gene therapy for Duchenne muscular dystrophy
NTLA	Intellia Therapeutics	Small/Mid	Speculative	Check live price	—	In vivo CRISPR gene editing
CRSP	CRISPR Therapeutics	Mid	Buy	Check live price	—	Casgevy gene-editing therapy (with Vertex)
KRYS	Krystal Biotech	Mid	Buy	Check live price	—	Gene therapy gel Vyjuvek for rare skin disease
RNA	Avidity Biosciences	Small/Mid	Buy-leaning	Check live price	—	RNA-targeted therapeutics
VERA	Vera Therapeutics	Small	Speculative	Check live price	—	Autoimmune kidney disease therapeutics
XENE	Xenon Pharmaceuticals	Small/Mid	Buy	Check live price	—	KV7 channel opener for epilepsy/neuro
VKTX	Viking Therapeutics	Small/Mid	Buy	Check live price	—	Oral & injectable GLP-1 obesity candidates
CRNX	Crinetics Pharmaceuticals	Small/Mid	Buy	Check live price	—	Oral therapies for endocrine disorders

7

Managed Care & Health Insurers

Medical cost ratios, Medicare Advantage rates, and the 2026 sector-wide relief rally.

Ticker	Company	Cap	Rating	Price	Target	What they do
UNH	UnitedHealth Group	Large	Buy	Check live price	~$357–$450	Largest U.S. insurer; UnitedHealthcare + Optum
ELV	Elevance Health	Large	Buy/Neutral	Check live price	~$405	Blue Cross Blue Shield plans, Medicaid/MA
HUM	Humana	Mid/Large	Mixed	Check live price	~$210–$254	Medicare Advantage-focused insurer
CI	Cigna Group	Large	Mixed	Check live price	~$304–$400	Commercial insurance + Evernorth/Express Scripts
CVS	CVS Health	Large	Buy-leaning	Check live price	—	Retail pharmacy, Aetna insurance, Caremark PBM
CNC	Centene	Mid	Mixed	Check live price	—	Medicaid/ACA marketplace insurer
MOH	Molina Healthcare	Mid	Mixed	Check live price	—	Medicaid/Medicare/Marketplace insurer
OSCR	Oscar Health	Small	Speculative	Check live price	—	Tech-driven ACA marketplace insurer

8

Hospitals & Health Systems

For-profit hospital operators navigating Medicaid policy risk and wage inflation.

Ticker	Company	Cap	Rating	Price	Target	What they do
HCA	HCA Healthcare	Large	Buy	$315	~$415–$520	190+ acute-care hospitals across the U.S. & England
UHS	Universal Health Services	Mid/Large	Buy-leaning	Check live price	—	Acute care + behavioral health hospitals
THC	Tenet Healthcare	Mid	Mixed	$171	—	Hospitals, ambulatory surgery centers
CYH	Community Health Systems	Small	Cautious	Check live price	—	Community hospital operator
ACHC	Acadia Healthcare	Small/Mid	Mixed	$25	—	Behavioral health & substance use facilities
DVA	DaVita	Mid	Mixed	Check live price	—	Dialysis/kidney care centers
EHC	Encompass Health	Mid	Buy-leaning	Check live price	—	Inpatient rehabilitation hospitals

9

Healthcare IT & Digital Health

Clinical software, telehealth, and AI tools rapidly resetting margin expectations.

Ticker	Company	Cap	Rating	Price	Target	What they do
VEEV	Veeva Systems	Large	Buy	Check live price	—	Cloud software for life sciences (CRM, regulatory)
DOCS	Doximity	Mid	Volatile / Buy-leaning	Check live price	~$40–$65	Physician network + AI tools (DocsGPT, Scribe)
TDOC	Teladoc Health	Small/Mid	Hold/Cautious	Check live price	—	Virtual care, BetterHelp mental health platform
PHR	Phreesia	Small/Mid	Mixed	Check live price	—	Patient intake/engagement software
OMCL	Omnicell	Small/Mid	Buy-leaning	Check live price	—	Medication management automation
HQY	HealthEquity	Mid	Mixed	Check live price	—	HSA/consumer-directed healthcare accounts
WAY	Waystar Holding	Mid	Buy-leaning	Check live price	—	Healthcare payments & revenue cycle software
TEM	Tempus AI	Mid	Speculative	Check live price	—	AI-driven precision medicine platform
GDRX	GoodRx Holdings	Small	Mixed	Check live price	—	Prescription discount platform

10

Diabetes Care & Endocrinology Devices

CGMs and insulin pumps fighting the GLP-1 demand-destruction narrative.

Ticker	Company	Cap	Rating	Price	Target	What they do
DXCM	DexCom	Mid/Large	Buy	$71	~$64–$95	Continuous glucose monitoring (CGM) systems
PODD	Insulet	Mid/Large	Buy	$154	~$190	Omnipod tubeless insulin pump
TNDM	Tandem Diabetes Care	Small/Mid	Buy	$23	~$28–$31	t:slim X2 & Mobi insulin pumps
BBNX	Beta Bionics	Small	Hold/Neutral	$16	—	iLet bionic pancreas automated insulin delivery
ABT	Abbott (Diabetes Care)	Large	Buy	$92.71	~$128	FreeStyle Libre CGM franchise
SENS	Senseonics	Small	Speculative	Check live price	—	Long-term implantable CGM sensors

11

Dental & Vision

Clear aligners, contact lenses, and the eye-care names riding elective-procedure demand.

Ticker	Company	Cap	Rating	Price	Target	What they do
ALGN	Align Technology	Mid/Large	Mixed	$167	—	Invisalign clear aligners, iTero scanners
XRAY	Dentsply Sirona	Small/Mid	Mixed	$10	—	Dental equipment, consumables, technology
NVST	Envista Holdings	Mid	Buy-leaning	$30	~$28	Nobel Biocare, Ormco, DEXIS dental brands
COO	The Cooper Companies	Large	Buy-leaning	Check live price	~$91	CooperVision contact lenses, CooperSurgical
ALC	Alcon	Large	Buy-leaning	Check live price	—	Surgical & vision care eye products
BLCO	Bausch + Lomb	Mid	Mixed	Check live price	—	Eye health: surgical, vision care, pharma
HSIC	Henry Schein	Mid/Large	Hold-leaning	Check live price	—	Distributor of dental & medical products
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL)

Sample Portfolio Mixes: Aggressive → Conservative

Four illustrative healthcare-sector tilts — purely educational examples of how the names above might be combined at different risk levels. Not a recommendation. These are hypothetical allocations for discussion purposes only and ignore your personal tax situation, time horizon, and existing holdings.

AGGRESSIVE

GROWTH

BALANCED

CONSERVATIVE

🔥 Aggressive Growth Mix

High volatility · binary catalysts · small/mid-cap heavy

25%Mid/small-cap biotech — ARGX (autoimmune drug Vyvgart), CRSP (gene editing), KRYS (gene therapy), VKTX (oral GLP-1)

20%Speculative cardio & gene-therapy — CRDL, OBIO, NTLA, SRPT

20%Digital health / AI diagnostics — TEM (AI precision medicine), DOCS (physician network), GH (liquid biopsy)

15%Emerging device disruptors — BBNX (bionic pancreas), ASXC (laparoscopic robotics), TMDX (organ transport)

20%High-growth large-cap anchor — ISRG (surgical robots), LLY (GLP-1 drugs)

📈 Growth-Tilted Mix

Established growth leaders · moderate volatility

20%GLP-1 / large-cap pharma growth (LLY, NVO, VRTX)

20%Surgical robotics (ISRG, MDT)

15%Diabetes devices (DXCM, PODD)

15%Diagnostics growth (GH, NTRA, EXAS)

15%Selective mid-cap biotech (ARGX, KRYS)

15%Managed care recovery play (UNH, HUM)

⚖️ Balanced Mix

Blend of growth and ballast across specialties

20%Diversified MedTech large-caps (MDT, SYK, ABT)

20%Large-cap pharma (JNJ, LLY, MRK)

15%Managed care (UNH, ELV)

15%Hospitals (HCA, UHS)

15%Diagnostics & labs (DGX, TMO)

15%Dental/vision & diabetes devices (COO, DXCM)

🛡️ Conservative / Defensive Mix

Dividend-payers · large, diversified, lower-beta names

30%Diversified pharma dividend payers (JNJ, ABBV, PFE)

25%Mega-cap MedTech (MDT, ABT)

20%Managed care blue-chip (UNH, ELV)

15%Hospital operator with scale (HCA)

10%Diagnostics utility-like cash flow (DGX, LH)

🚀 Emerging Companies With Potential Exponential Growth

Smaller, earlier-stage names pulled from across every specialty above that carry outsized — and outsized-risk — upside according to current Street commentary. These are higher-volatility, often pre-profit or single-catalyst companies. Treat this as a watchlist starting point, not a buy list.

Cardiology

CRDL — Cardiol Therapeutics

Strong Buy consensus from a small analyst panel; speculative CBD-based anti-inflammatory cardiac pipeline with Phase 3 catalysts ahead.

Cardiology

OBIO — Orchestra BioMed

Bioelectronic hypertension therapy partnered with Medtronic; binary upside tied to BACKBEAT trial data expected 2027.

Biotech

VKTX — Viking Therapeutics

Oral & injectable GLP-1 candidates; analysts flag among the highest implied upside in cardiometabolic biotech baskets.

Biotech

CRNX — Crinetics Pharmaceuticals

Oral endocrine-disorder therapies; high implied upside in recent genomics/biotech ETF rankings.

Biotech

XENE — Xenon Pharmaceuticals

KV7 channel opener for epilepsy/depression; William Blair 2026 top pick with late-stage data readouts on deck.

Biotech

KRYS — Krystal Biotech

Commercial-stage gene therapy (Vyjuvek) with a broader redosable gene-therapy platform; William Blair top pick.

Diagnostics

GH — Guardant Health

Biggest analyst-estimate beat among diagnostics peers in recent earnings; liquid biopsy/MRD growth story.

Diagnostics

RDNT — RadNet

Outpatient imaging network layering in an AI imaging division — a structural growth story beyond pure imaging volume.

Healthcare IT

TEM — Tempus AI

AI-driven precision medicine platform; high-growth, high-volatility name at the intersection of diagnostics and software.

Healthcare IT

WAY — Waystar Holding

Revenue-cycle/payments software riding hospital AI-automation adoption.

Robotics/MedTech

TMDX — TransMedics

Organ preservation & transplant logistics — building an end-to-end transplant ecosystem with first-mover scale.

Robotics/MedTech

ASXC — Asensus Surgical

Small-cap digital laparoscopic robotics name — high-risk, early-stage challenger to the ISRG/MDT duopoly.

Orthopedics

ATEC — Alphatec Holdings

Spine-focused challenger gaining share against legacy orthopedic majors with differentiated navigation tech.

Diabetes Care

BBNX — Beta Bionics

iLet bionic pancreas — newer entrant in automated insulin delivery still scaling commercial adoption.

Dental/Vision

NVST — Envista Holdings

Fastest revenue growth of its dental peer group last quarter, with consensus price target recently raised.

Compiled June 30, 2026 from stockanalysis.com, TipRanks, MarketBeat, Public.com, Simply Wall St, Investing.com, Zacks, Yahoo Finance, StockStory, and 24/7 Wall St.
Not investment advice. Not a recommendation to buy or sell any security. The author is not a financial advisor. Ratings and targets change frequently — verify current data before acting.